ニュースルーム

Innovation is an everyday occurrence at Geistlich. The film “The Art of Innovation” is designed to give a better idea of what this everyday life looks like and to make it accessible to the public at large.

Following on from the bone replacement material Geistlich Bio-Oss^®, the Japanese authorities have now also granted a licence to Geistlich Bio-Gide^®. The sales launch of the collagen membrane for bone regeneration is to take place shortly.

With immediate effect two new laws in the US and France will regulate collaboration between medicine and industry. The goal of both laws is to ensure greater transparency in future towards the general public and thus prevent conflicts of interest. All payments from manufacturers to the medical profession will be published on the Internet.

In October 2013, Dr Peter Geistlich, the President of the Board of Directors of Geistlich Pharma AG, together with Geistlich Pharma AG in the USA, launched the Osteo Science Foundation which has its registered office in Philadelphia. The goal of the Foundation is to support and promote independent research in North America in oral and maxillofacial surgery and to put its results from theory into practice.

In September, the 3rd Central Switzerland Economic Forum was held on the Pilatus on the topic of "Education – Innovation – Workforce". Paul Note, CEO of Geistlich Pharma AG, was the podium guest at the workshop "Innovation and knowledge transfer". With renowned representatives from business and education, he discussed the topic: What promotes innovations and drives the transfer of knowledge; where are the obstacles?

Researchers of the University of Zurich has presented new results from a long-term study over 12 to 14 years. The study shows that implants placed simultaneously with guided bone regeneration (GBR) have a high survival rate not significantly different to implants placed in ample vital bone.

The Osteology Foundation is celebrating its 10th anniversary at the International Symposium in Monaco. Geistlich Pharma, together with Dr. Peter Geistlich, set up the Foundation in 2003 in order to promote research in regenerative dentistry and make it available to practitioners. Co-operations between research, hospitals and industry have since made possible better treatment methods for the patients.

Geistlich Biomaterials showed many visitors the innovations in Geistlich products at its 160 m2 stand at the International Dental Show (IDS) in Cologne between 12th and 16th March 2013. Geistlich Biomaterials' presentation this year was all about treating extraction sockets with the Geistlich Combi-Kit Collagen. The Geistlich Bio-Oss Pen^® and the spectacular 3D movies on indications in the regeneration of hard and soft tissue aroused great interest.

Geistlich Pharma AG is able to look back on a varied 2012 with a sense of satisfaction. Its good geographical mix and focus on a long-term strategy have once again delivered a good set of figures. Nevertheless, the Swiss family company has not been immune to slower growth within the industry as a whole.